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ABSTRACT
Age-related macular degeneration, which was once thought to
be a disease mainly found in Caucasian populations in Europe
and America, is now also appearing more frequently among
non-white populations in the developing world. Ophthalmic
practitioners should be aware of this. This paper reviews
current concepts in the pathogenesis and management of age-
related macular degeneration as found in Pubmed journals
over the past ten years with a view to recommending optimal
treatment regimes for African populations. 
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause
of visual impairment among the elderly in the developed
world.  The disease was initially thought to be relatively rare1
in developing countries,  but recent studies have shown that2
it is more prevalent than earlier believed, particularly in India3
and Nigeria.  Age-related macular degeneration is coming up4
more frequently in clinical studies as an important cause of
low vision in the western  and south eastern parts of5,6,7 8, 9 
Nigeria. There is no accurate database on the prevalence of
this disease in developing countries. This is probably due to
the paucity of trained vitreoretinal surgeons and the non
availability of equipment needed to make an accurate
diagnosis of this important cause of low vision and blindness
in the aging segments of African populations. As people are
living longer due to improved health care, it is expected that
the number of persons with the disease will continue to rise.
This review discusses current concepts such as the role of
genetics in the aetiopathogenesis of AMD and the use of
antiVEGF (vascular endothelial growth factor inhibitors) in its
management and its suitability for African patients.
METHODOLOGY
A Pubmed search was conducted using the Internet. The
search was limited to publications within the last ten years.
Only studies that discussed pathogenesis and treatment were
considered. The review of literature revealed very few studies
from Nigeria and these studies only mention AMD as one of
the causes of low vision in Nigeria.   
AETIOPATHOGENESIS OF AMD
Genetics
AMD is a multifactorial disease.  Its pathogenesis results from10
an interplay of genetics, the environment, and behavioural
factors. Family-based studies and molecular genetics have
consistently shown that complement factor H (CFH) and
LOC387715 genes on chromosome 1 and 10 respectively are
important in the pathogenesis of age-related macular
degeneration.  In complement factor H polymorphism,11,12
histidine is substituted with tyrosine at position 402 on
chromosome 1 (Y402H).  This results in the production of an12
abnormal variant of complement factor H.  Under normal
conditions, this factor is involved in the inhibition of the
alternate pathway of the complement  through its ability to
bind with C-reactive protein, thereby down regulating
inflammation.  The abnormal variant of complement factor H12
produced from the defective gene binds sparingly to the C-
reactive protein and this results in an increase in inflammation
producing RPE damage and drusen formation, which are
important stages in the pathogenesis of AMD.  Increased13
levels of C-reactive proteins are associated with AMD.  The14
exact role of the LOC387715 gene is still being investigated. It
is associated with neovascular AMD.  15
Environmental factors, such as solar exposure, are also
implicated in the aetiopathogenesis of AMD.  The Age-16
Related Eye Disease Study (AREDS)  has shown the benefits17
of nutritional supplements in patients with AMD. Other
factors associated with AMD development include, smoking,
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increasing age, hyperopia, a high body mass index, being
Caucasian, hypertension, lens opacity and the presence of
large drusens.  The intake of fish is beneficial.  18 19
CLINICAL PRESENTATION
Classification of AMD20
The International Classification and Grading System
differentiates age-related maculopathy (ARM), which includes
all manifestations of age-related macular abnormalities that
are not attributable to any other cause except AMD. The late
stages of ARM are named age-related macular degeneration
(AMD) and these include both ‘dry’ and ‘wet’ stages of
AMD.20
FEATURES
A defining feature of ARM is the presence of drusen.  Drusen
are ‘discrete whitish-yellow spots . . . which are external to the
neuroretina or retina pigment epithelium (RPE)’. ‘Hard’
drusen, however, are not necessarily a feature of ARM, as they
may be present in the eyes without ARM. However, ARM will
not be diagnosed if there are no drusen or if only small drusen
(less than 63 microns) are present.
Features of early stages of ARM
1. Multiple small drusen and few intermediate drusen (63-
124 microns in diameter).
2. Areas of hyperpigmentation associated with drusen.
3. Areas of hypopigmentation associated with drusen.
Intermediate ARM
According to the AREDS report, wherever a number of ‘large’
drusen (large drusen is defined as >=125 :M) were present in
both eyes, there was a greater risk of development of AMD in
either eye, than if the presence of large drusen occurred in
only one eye. In the simplified severity scale described in the
AREDS report number 18, drusen are considered a risk factor
only if an individual drusen is large (defined as >125 :M).
Drusen size is used instead of drusen area, because it is easier
to estimate the size using an ophthalmoscope. The figure
125:M was selected because it approximates the size of a
normal retinal vein at the disc margin.20
The presence of  multiple intermediate or any large
drusen is considered an intermediate stage of ARM. The
report also showed that patients with ‘intermediate’ drusen,
(defined as any drusen >63 :M but <=125 :M), or many small
drusen, had only a 1.3% chance of developing advanced AMD
over 5 years.  17
LATE ARM  (AMD)
Dry AMD (or 'geographic atrophy')
Dry AMD is characterized by sharply demarcated areas of
hypopigmentation in which choroidal vessels (which are at
least 175 :m in diameter) are more visible than in
surrounding areas (see figure 2).
Figure 2. Intermediate ARM  with multiple medium to large
drusens (from  Neil M Bressler MD, Johns Hopkins University
School of Medicine).
Wet AMD ('neovascular', 'disciform', or 'exudative'
AMD)
Wet AMD is also associated with the following features:
1. RPE detachments, which may be associated with
neurosensory retinal detachment
2. Subretinal or sub-RPE neovascular membranes
3. Epiretinal, intraretinal, subretinal, or subpigment
epithelial scar/glial tissue or fibrinlike deposits
Figure 1. Intermediate ARM  with m ultiple m edium  to large drusens
(from  Neil M Bressler MD, Johns Hopkins University School of Medicine).
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4. Subretinal haemorrhages not related to other retinal
vascular disease
5. Hard exudates (lipid) related to other ARM findings but
not related to other vascular diseases
Figure 3. Subretinal neovascular membrane, with subretinal
blood (From  LV Prasad Eye Institute, Hyderabad, India) 
Figure 4. Choroidal neovascular mem branes w ith hard
exudates. (From LV Prasad Eye Institute, Hyderabad, India)
Figure 5. Scarred chroidal neovascular membrane (from
LV Prasad Eye Institute, Hyderabad, India)
MANAGEMENT OF AMD
Investigative procedures 
Slit lamp biomicroscopy.  A detailed slit lamp biomicroscopy
with a contact (Goldman's 3-mirror lens) or non-contact
fundus lens (+78 or +90D) with a bright thin beam is required
for detecting choroidal neovascular membranes (CNVM) and
fluid due to stereopsis offered by these lenses.
Flourescein angiography. This functional invasive test is an
essential tool in making accurate diagnosis of classic and
occult choroidal neovascular membranes. Indocyanine
angiography(ICG) is useful in detecting occult CNVM
especially when blood is blocking fluorescence.
 
Optical coherence tomography (OCT). Optical coherence
tomography is a non invasive investigation that uses the
reflection of infrared light to construct the histology section of
the posterior pole similar to ultrasonography. It is an excellent
tool for patients who are not suitable for flourescein
angiography. OCT also helps to define the layers of the retina
involved, it detects the presence of retinal oedema, cysts, and
neovascular membranes. It also differentiates Type I (sub RPE)
from Type II (sub neurosensory retina) CNVM. Patient follow
up and education is made easier with OCT.  
TREATMENT
Non-neovascular AMD
If AMD is at the intermediate stage, patients should be
advised to start taking the nutritional/vitamin antioxidant
supplements which were found effective in the AREDS
study,  provided the individual has not had any adverse17
reaction to taking any of the components of this formulation.
The antioxidants are taken at a daily dose of:
1. 500 mg of vitamin C
2. 400 International Units of vitamin E 
3. 5 mg of beta carotene
4. Zinc supplement at a dose of 80 mg
5. Cupric oxide at 2 mg 
Cupric oxide is added to reduce the risk of copper deficiency
anaemia associated with taking a zinc supplement.  Cigarette17
smokers should be warned of the risk of developing lung
cancer with a high dose of beta carotene.  Patients with21
bilateral advanced AMD, but with good vision in at least one
eye should also be advised to start taking the above
supplements. The AREDS report indicates that the above
dietary supplement decreases the risk of vision loss in the eye
with advanced AMD with visual acuity of 20/100 or better.17
Ophthalmologists in Nigeria should work together with the
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pharmaceutical companies to investigate this vitamin
formulation and explore the possibility of making it available
as an eye supplement.
Neovascular AMD
It has been shown that vascular endothelial growth factors
(VEGF) play a significant role in the pathogenesis of
neovascular AMD.  The new vessels formed can either be22
within the retinal, sub retinal or sub retinal pigment
epithelium (RPE). Although it occurs in only 15% to 20% of
AMD populations, it more commonly results in severe vision
loss compared with non-neovascular AMD. The origins of23  
these new blood vessels include the choroid (choroidal
neovascular membrane  (CNVM)) or may start within the
retina and proliferate downward, in which case they are called
retinal angiomatous proliferation (RAP). Flourescein
angiography reveals patterns such as: predominantly classic
(clearly defined neovascular network >50% of lesion area),
occult (poorly defined new vessles), minimally classic (classic
< 50% of lesion area), or predominantly scarred. Bleeding and
exudation from these new vessels result in visual loss. The end
stage is a fibrotic or disciform scar.23
Prior to the year 2000, laser treatment was the standard
for classic CNVM. This form of treatment, however, was not
satisfactory and sometimes resulted in scotoma formation,
especially for lesions close to the fovea. Secondly,
neovascularization often recurred at the edges of the laser scar.
In 2000, verteporfin photodynamic therapy (PDT) supplanted
macular photocoagulation to become the dominant treatment
for neovascular AMD.24
However, patients receiving PDT still had loss of vision,
and the 'benefit' of PDT is measured in terms of decreasing the
loss of vision, rather than regaining lost vision. The limitations
of PDT have led to more research efforts to find better
methods for treating neovascular AMD. Steroids were the next
choice of treatment.  Triamcinolone was combined with PDT25
with improvement or gain in vision.  Complications of26
intravitreal triamcinolone include cataract formation and
glaucoma. This led to the development of angiostatic steroids
with no glucocorticoid activity that could inhibit angiogenesis
in an in-vitro model. Anecortave acetate is an angiostatic27
steroid which is given as a subtenon's injection every 6 months
in the treatment of neovascular AMD. It was found to be
superior to no treatment  but inferior to PDT. In Nigeria,28
where PDT is not readily available, the need arises to look for
more affordable treatment, such as intravitreal injections. 
V A S C U L A R  E N D O T H E L I A L  F A C T O R
INHIBITORS (ANTI-VEGF)
Investigators have shown that VEGF play a significant role in
the pathogenesis of neovascular AMD, hence, they are22, 29-31 
the target of current treatment modalities. In the year 2005, the
selective anti-VEGF aptamer pegaptanib (Macugen ) showedR
superiority over available treatment when given
intravitreally.  Pegaptanib is an RNA oligonucleotide aptamer31
that binds with VEGF. About a few months later, the
nonselective antiBVEGF bevacizumab (Avastin ) moleculeR
also became available. Bevacizumab (Avastin) is a full32-34 
length antibody against VEGF and a humanized monoclonal
antibody synthesized using recombinant DNA technology.35
Intravitreal bevacizumab (at a dose of 1.25mg in 0.05ml)
has many advantages over all the other treatments discussed
so far. First, it seems to lead to an improvement in vision.36
Second. it is safe, and third, it is less expensive than PDT or
pegaptanib.  Several reports have described its efficacy.  In33 36-39
July 2006, ranibizumab (Lucentis ) became commerciallyR
available in the United States, as the first medication which
showed a proven improvement in visual acuity in a
randomized controlled trial and was approved by the FDA for
the treatment of neovascular AMD.  It is an anti-VEGF40
antigen-binding antibody fragment (Fab) that is specific for
165VEGF . Ranibizumab is administered as an intravitreal
injection (0.3mg or 0.5mg), and it has now been tested in a
number of clinical trials for the treatment of neovascular
AMD.  Two major phase 3 clinical trials for ranibizumab40,41
known as the MARINA  and ANCHOR  have demonstrated* **
superiority of ranibizumab over sham and PDT.42
Officials of The National Eye Institute (NEI), USA
announced in October 2006 that they will launch their own
clinical trials comparing outcomes of both Lucentis and
Avastin as macular degeneration treatments. The British
Journal of Ophthalmology in July 2006 reported results of one
Internet survey among eye doctors who reported no adverse
side effects related to the use of Avastin for macular
degeneration, seemingly because relatively low doses of the
drug are injected into the eye. But other researchers43 
commenting in the journal pointed out that long-term safety
risks of Avastin remain unknown. 
In May 2007, the British Journal of Ophthalmology
published a cost analysis comparing the two treatments.
Researchers concluded that Lucentis, which is about 50 times
more expensive than Avastin, would need to be 2.5 times
more effective to justify the additional cost.  Research44
indicates that at present, Avastin appears to be a better buy for
the money.
In Nigeria, ophthalmologists should run a randomized
trial using bevacizumab; if the results are positive, the
Minimally classic/occult trial of the Anti-VEGF antibody*
Ranibizumab In the Treatment of Neovascular AMD.
ANti-VEGF antibody for the treatment of predominantly classic**
choroidal neovascularization in AMD.
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pharmaceuticals could manufacture bevacizumab as a cheaper
alternative.
VEGF-trap (Regeneron ) R
The VEGF-trap consists of an Fc fragment linked to the
extracellular portions of the VEGFR1 and VEGFR2 receptors.
It is injected intravitreally, where it will bind with free VEGF
and prevent activation of VEGF receptors. In-vitro studies are
promising.45-46
Small inhibitory RNAs (siRNA)
These are short double stranded RNA molecules that inhibit
translation of the native mRNA from which they are derived.
In-vitro studies have demonstrated that anti-VEGF siRNAs
were able to decrease the expression of the human VEGF gene
and appeared to stop the  growth of laser induced CNV.  A47
new anti-VEGF siRNA called bevasiranib or Cand5, which is
injected intravitreally, is under investigation, and so far, has
been shown to be effective.48
The International Conference on Age-Related Macular
Degeneration, held at Aravind Eye Hospital, India, in January,
2007 recommended the following treatment modality for
neovascular AMD.
1. The treatment of extra foveal CNVM is laser
treatment.
2. The first line treatment of subfoveal CNVM is
intravitreal ranibizumab.
3. Bevacizumab is used when ranibizumab is not
available, or when the patient could not afford the
cost of ranibizumab.
4. Pegaptanib (Macugen) is considered when the above
medications are not available.
5. The only consideration for PDT is when the patient




Age-related macular degeneration is no longer a disease
confined to developed countries, but occurs throughout the
world. Ophthalmologists should carry out careful and detailed
evaluations of the macular area in their elderly patients. The
recent explosion in research and publications in this area
worldwide is an indication of what to expect in the future.
In developing countries like Nigeria, ophthalmologists
should work together with the pharmaceutical companies to
conduct clinical trials using intravitreal injections, such as
bevacizumab to determine the most effective treatment for
subfoveal CNVM. Where this is not possible, intravitreal
triamcinolone should be investigated, as this is readily
available in Nigeria. The most commonly reported side effects
of intravitreal injections included red eye (conjunctival
haemorrhage), eye pain, small specks in the fields of vision
(floaters), increased eye pressure, and inflammation of the eye.
Serious side effects, which were rare and often related to the
injection procedure, included severe inflammation of the
interior of the eye (endophthalmitis), intraocular
inflammation, retinal detachment, retinal tear, increased eye
pressure, and traumatic cataract.  These complications should49
be borne in mind when recommending this treatment.
Multivitamins in AREDs recommended combinations are
available and should be prescribed for patients with the
intermediate stage of AMD.
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